Abstract
The influence of operative treatment and chemotherapy on the prognosis in 93 gastric cancer patients with liver metastasis was studied. Chemotherapy included the systemic administration of mitomycin C (MMC) (39 patients), an intra-hepatoarterial infusion of MMC (MMC IAC group) (19 patients) and an intra-hepatoarterial infusion of MMC and cisplatin (CDDP) (MMC + CDDP IAC group) (24 patients). Either MMC or MMC and CDDP were given in 1–4 courses every 3–4 weeks from the first one to two post operative weeks. The response rate was 4 per cent (1/23), 29 per cent (5/17) and 73 per cent (17/23) for MMC systemic administration, MMC IAC and MMC + CDDP IAC, respectively, with a significantly high rate of effectiveness for the MMC + CDDP IAC. In addition, regarding the median survival period, the MMC + CDDP IAC group showed 11.8 months, as compared with 2.9 months for other chemotherapeutic treatments, indicating a good prognosis regardless of any possible resection of the primary lesion. A Cox proportional hazard model revealed the treatment by MMC + CDDP IAC alone to be a significant independent factor. These results indicated that MMC + CDDP intra-arterial chemotherapy is an effective approach to gastric cancer with liver metastasis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Moertel CG, Lavin PT (1979) Phase II–III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63:1863–1869
Maeta M, Koga S, Yoshioka H, Murakami A, Wakatsuki T (1985) Intra-hepatoarterial infusion of cis-diamminedichloroplatinum (II) and 5-fluorouracil clinically effective for malignant liver tumors. Jpn J Surg 15:318–320
Okuyama K, Isono K, Juan IK, Onoda S, Ochiai T, Yamamoto Y, Koide Y, Satoh H (1985) Evaluation of treatment for gastric cancer with liver metastasis. Cancer 55:2498–2505
Nishi M, Tamura T (1962) Clinical study of stomach cancer with hepatic metastasis (in Japanese). Jpn J Cancer Clin 8:433–442
The gastrointestinal tumor study group (1979) Phase II–III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63:1871–1876
Leichman L, McDonald B, Dindogru A, Samson M, Vaitkevicius VK (1984) An active drug in the treatment of disseminated gastric cancer. Cancer 53:18–22
Quei β er W, Flechtner H (1986) Chemotherapy of advanced gastric carcinoma. Onkologia 9:319–331
Preusser P, Wilke H, Achterrath W, Balleisen NL, Meyer J, Van de Loo J (1986) Advanced inoperable stomach cancer. A pilot study with the combination etoposide, Adriamycin and cisplatin. Anticancer Res 6:1195–1196
Matuki N, Sakuma H, Sawa T, Yagi M, Hagino S, Katayama K, Uogishi M, Ueno K, Sawazaki K, Yonemura Y, Kasai M, Shima K, Hirono T, Yoshimitsu S, Miyazaki I (1988) Effect of PMU therapy (CDDP, MMC and UFT) against terminal gastric cancer (in Japanese). Jpn J Cancer Chemother 15:655–659
Cox DR (1981) Regression model and life table. J Stat Soc 34:187–220
Japanese Research Society Gastric Cancer (1981) The general rules for the gastric cancer study in surgery and pathology. Jpn J Surg 11:127–139
Kuroda T, Tuji M, Kita I, Ohta T, Ueno K (1986) Survival following varied treatments for stomach cancer with metastasis to the liver (in Japanese). J Jpn Soc Clin Surg 47:9–17
Hamazoe R, Koga S, Maeta M, Murakami A, Inoue Y, Shabana M (1989) Intra-hepato-arterial chemotherapy combined with hyperthermic treatment: Clinical results for metastatic cancer of the liver and effects on correct hepatic blood flow (in Japanese). Jpn J Cancer Chemother 16:3032–3035
Tuji Y, Nishimura A, Katsuki Y, Yasuda T (1989) Evaluation of long survival cases treated with intra-arterial chemotherapy using implantable reservoirs (in Japanese). Jpn J Cancer Chemother 16:2944–2948
Okuyama K, Onoda S, Tohnosu N, Koide Y, Awano T, Ozaki M, Ochiai T, Gunji Y, Matsubara H, Kinoshita H, Nakaichi H, Sano T, Isono K (1989) Survivor for over two years from intraarterial infusion chemotherapy in gastric cancer with liver metastases (in Japanese). Jpn J Cancer Chemother 16:2932–2935
Repta AJ, Long DF (1980) Reactions of cisplatin with human plasma and plasma fractions. In: Prestayko AW, Crookes (eds) Cisplatin: Current status and new development. Academic, New York, pp 285–304
Wile AG, Kar R, Cohen RA, Jakowatz JG, Opfell RW (1987) The pharmacokinetics of cisplatin in experimental regional chemotherapy. Cancer 59:695–700
Ohoyama S, Tanaka M, Kinoshita K, Ninomiya I, Yonemura Y, Miyazaki I, Endou Y, Sasaki T (1991) In vitro chemosensitivity test using collagen gel matrix for human gastric carcinomas. Jpn J Cancer Chemother 18:239–243
Maehara Y, Anai H, Masuda H, Tamada R, Sugimachi K, Inokuchi K (1985) In vitro chemosensitivity test of various human tumors evaluated by SDI (succinated dehydrogenase inhibition) test (in Japanese). Jpn J Cancer Chemother 12:2018–2023
Teicher BA, Grunner LJ, Road JA (1985) Chemopotentiation of mitomucin C cytotoxicity in vitro by platinum complexes. Br J Cancer 52:833–839
Schabel FM, Trader MW, Laster WR, Corbett TH, Griswold DP (1979) Cis-dichloroplatinum (II): Combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63:1459–1473
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yonemura, Y., Matuki, N., Sakuma, H. et al. Effect of intra-hepatoarterial infusion of MMC and CDDP for gastric cancer patients with liver metastases. Surg Today 22, 253–259 (1992). https://doi.org/10.1007/BF00308831
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00308831